source
- FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer PatientsThe U.S. Food and Drug Administration today approved TREGZI, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult pat…fda press · 1mo ago↗ source
- Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot programThe planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.BioPharma Dive · 1mo ago↗ source
- Viridian may have edge over Amgen in eye drug showdown, analysts argueThe FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.